BLX-0631

BLX-0631 is a potent, highly selective, orally available small molecule inhibitor of the proto-oncogene serine/threonine-protein kinase Pim-1 (PIM1). It was developed by Biolexis Therapeutics for potential use in oncology and immune-mediated diseases. The compound demonstrates strong inhibitory activity against PIM1 (IC50 = 15 nM), with selectivity over related kinases PIM2 and PIM3. Preclinical studies showed that BLX-0631 reduces pro-inflammatory cytokines such as IL-1β and TNF-α by more than 80%, and demonstrated efficacy in systemic lupus erythematosus (SLE) mouse models by improving renal function markers and histopathology scores. Its mechanism of action targets cell proliferation, differentiation, survival pathways relevant to cancer and autoimmune disease pathogenesis. Despite promising preclinical data, development has been discontinued at the preclinical stage for all indications[1][2][7].